1
Gary R Petersen, K I Dayalu: Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof. Solvay Animal Health, John P White, October 15, 1996: US05565205 (57 worldwide citation)

This invention provides a bacterin comprising a virulent Mycoplasma hyopneumoniae isolate, inactivated with binary ethyleneimine, in an amount effective to immunize a swine against infection by Mycoplasma hyopneumoniae and a suitable physiologically acceptable carrier. The invention also provides a ...


2
Karel Z Mewman Jr, John L Tedesco, Thomas C Gore, Gary R Petersen, Virginia M Brothers, James G Files, Leland S Paul: Antigenic proteins and vaccines containing them for prevention of coccidiosis caused by eimeria Eimeria necatrix and Eimeria tenella. Solvay & Cie, John P White, July 2, 1991: US05028694 (29 worldwide citation)

A purified antigenic protein has been obtained which is capable of inducing in a chicken an immune response conferring protection against infection by Eimeria necatrix or Eimeria tenella. The protein has a molecular weight of about 26,000 and is composed of two polypeptides joined by a disulfide bon ...


3
Ellan Welniak, Gary R Petersen: Methods for the cultivation of infectious laryngotracheitis virus. Solvay Animal Health, Oblon Spivak McClelland Maier & Neustadt, August 22, 1995: US05443982 (1 worldwide citation)

This invention involves a chemically transformed chicken hepatocyte derived cell line which is capable of efficiently supporting replication of infectious laryngotracheitis virus (ILTV) and methods for cultivating ILTV using this hepatocellular carcinoma cell line. The virus harvested from these con ...


4
Mark D Cochran, Gary R Petersen, Stephen V Lair, Richard M Synenki: organisms and vaccine, Recombinant attenuated. Intervet, October 5, 2010: US07807456

The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine con ...


5
Mark D Cochran, Gary R Petersen, Stephen V Lair, Richard M Synenki: organisms and vaccine, Recombinant attenuated. Intervet, June 8, 2010: US07732187

The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine con ...


6
Mark D Cochran, Gary R Petersen, Stephen V Lair, Richard M Synenki: Recombinant attenuated clostridium organisms and vaccine. Schering Plough Corporation, Patent Department, December 13, 2007: US20070286874-A1

The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine con ...


7
Mark D Cochran, Gary R Petersen, Stephen V Lair, Richard M Synenki: Recombinant attenuated clostridium organisms and vaccine. Intervet, Merck, Patent Department, July 1, 2010: US20100166800-A1

The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine con ...



Click the thumbnails below to visualize the patent trend.